KFAS
PCVX icon

Keating Financial Advisory Services’s Vaxcyte PCVX Stock Holding History

Keating Financial Advisory Services’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98K Buy
34
+1
+3% +$54 ﹤0.01% 1955
2026
Q1 		$1.92K Buy
33
+28
+560% +$1.52K ﹤0.01% 1866
2025
Q4 		$231 Buy
+5
New +$224 ﹤0.01% 2056

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Keating Financial Advisory Services's PCVX Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Vaxcyte (PCVX) stake by 3% in Q2 2026, buying an estimated $54 and bringing the position to 34 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Keating Financial Advisory Services first reported a position in PCVX in Q4 2025 and has held it in 3 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Keating Financial Advisory Services held 34 shares of Vaxcyte worth $1.98K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Vaxcyte share in Q2 2026, an estimated $54.
  • Vaxcyte made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1955 holding.
  • Keating Financial Advisory Services first reported a position in Vaxcyte in Q4 2025 and has held it in 3 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.